##
##
||||Page|
|---|---|---|---|
|Contents|||Numbers|
|Legal and|administrative|information||
|Report of|the Trustees||3-10|
|Report of|the Auditors||11-13|
|Statement|offinancial|activities|14|
|Charity balance sheet|||15|
|Notes forming part ofthe financial statements|||16-24|
##
|Charity registration|Charity registration|number:
1129597|number:
1129597|||
|---|---|---|---|---|---|
|Company|registration||number:
6876186|||
|Directors|and|||||
|Trustees:|||Dr Kevin Moreton||24/11/15 —present|
||||Dr Jan Lowe||17/05/18 —present|
||||Dr Liz Miller||13/08/18 —present|
||||Dr LeoJames||28/03/19 —present|
||||Dr Anne Bertolotti||05/11/20 —present|
|Secretary:|||Mrs Josie Gowler FCA||18/04/18 —present|
|Registered|||MRC Laboratory ofMolecular|Biology||
|Office:|||Francis Crick Avenue|||
||||Cambridge
Biomedical Campus|||
||||Cambridge|||
||||CB2 OQH|||
|Auditors:|||Price Bailey LLP:|||
||||Tennyson
House|||
||||Cambridge
Business Park|||
||||Cambridge|||
||||CB4OWZ|||
|Bankers:|||Lloyds Bank PLC:|||
||||3Sidney Street|||
||||Cambridge|||
||||CB238tJ|||
|Solicitors:|||Harrison
Clark Rickerbys Limited:|||
||||50-60Station Road|||
||||Cambridge|||
||||CB12JH|||
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
|||||||Total Year|Total Year|
|---|---|---|---|---|---|---|---|
||||||Expendable|01/10/21|01/10/20|
||||Unrestricted|Restncted|Endowment|to|to|
||||Funds|Funds|Funds|30/09/22|30/09/21|
|||Note|f|E|f|f|E|
|Income:||||||||
|Donations
and legacies||3|28,701|35,506|0|64,207|216,440|
|Investment
Income||4|90,559|47,657|16,790|155,006|126,253|
|Trading income||14|172|0|0|172|169|
|Total Income|||119,432|83,163|16,790|219,385|342,862|
|Expenditure
on:||||||||
|Charitable
Activities|||70,905|21,856||92,761|54,418|
|Trading Activities|||3|0||3|38|
|Total Expenditure||5|70,908|21,856||92,764|54,456|
|Net Gains/(Losses)||||||||
|on Investments|||(201,377)|(105,985)|(37,339)|(344,701)|608,428|
|Net (Expenditure)|/|||||||
|Income|||(152,853)|(44,678)|(20,549)|(218,080)|896,834|
|Transfers
between|funds|||||||
|Net movement
in funds|||(152,853)|(44,678)|(20,549)|(218,080)|896,834|
|Fund Balances||||||||
|brought
forward at||||||||
|01October 2021|||2,031,465|1,032,144|368,443|3,432,052|2,535,218|
|Fund Balances||||||||
|carried forward at||||||||
|30September
2022|||1,878,612|987,466|34 .894|3.213.9 2|3,432.052|
##
##
||||||30/09/2022|30/09/2021|
|---|---|---|---|---|---|---|
|||||Notes|E|E|
|Fixed Assets|||||||
|Investments|||||2,852,106|2,896,807|
|TOTAL FIXEDASSETS|||||2,852,106|2,896,807|
|Current Assets|||||||
|Debtors: amounts|falling||due within one year|10|560|119,060|
|Cash at bank and in||hand|||382,021|429,539|
|TOTAL CURRENT ASSETS|||||382,581|548,599|
|Creditors: amounts||falling due within one year|||(20,715)|(13,354)|
|Net current assets|||||361,866|535,245|
|Net Assets|||||3,213,972|3,432,052|
|Funds ofthe charity|||||||
|Unrestricted
Funds|||||||
|General Funds|||||1,020,607|1,096,930|
|Designated
Funds|||||858,005|934,535|
||||||1,878,612|2,031,466|
|Restricted Funds|||||||
|Restricted
Funds|||||987,466|1,032,144|
|Expendable
Endowment|||Funds||347,894|368,443|
||||||1,335,360|1,400,588|
|Total Funds||||12|3,213,972|3,432,052|
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
|Donations|and legacies|||
|---|---|---|---|
|||Totalforthe|Total for the|
|||Year|Year|
|||01/10/2021 to|01/10/2020 to|
|||30/09/2022|30/09/2021|
|||E|E|
|Individuals||10,641|80,448|
|Legacies||0|100,000|
|Gift Aid||560|19,073|
|Corporate|Donors|53,006|16,919|
|||64,207|216,440|
##
|Investmen|t
Income|||
|---|---|---|---|
|||Total for the|Total forthe|
|||Year|Year|
|||01/10/2021 to|01/10/2020 to|
|||30/09/2022|30/09/2021|
|||E|E|
|Interest Receivable||8|18|
|Dividends|received from Investments|154,998|126,235|
|||155,006|126,253|
##
|||||Activites|Support||
|---|---|---|---|---|---|---|
|||||Undertaken|Costs|Total|
|||||Directly|(Note 6)|Funds|
|||||E|E|E|
|Promotion|and advancement||of||||
|education|and research|||84,816|7,945|92,761|
|Trading activities||||3|0|3|
|||||84,819|7,945|92,764|
|Analysis ofExpenditure||-Prior Year|||||
|||||Activites|Support||
|||||Undertaken|Costs|Total|
|||||Directly|(Note 6)|Funds|
|||||E|E|E|
|Promotion|and advancement||of||||
|education|and research|||48,620|5,798|54,418|
|Trading activities||||38|0|38|
|||||48,658|5,798|54,456|
##
|Analysis|of|Suppor|t Co|sts|||
|---|---|---|---|---|---|---|
||||||Totalforthe|Totalforthe|
||||||Year|Year|
||||||01/10/2021 to|01/10/2020|
||||||30/09/2022|to 30/09/2021|
||||||E||
|Professional||Fees|||1,621|1,308|
|Bank Fees|||||168|169|
|Trustee|Indemnity||Insurance||967|912|
|Accountancy||Services|||13|13|
|Governance||Costs|(See|note 7)|5,176|3,396|
||||||7,945|5,798|
|Analysis|of|Governance||Costs|||
||||||Total for the|Total for the|
||||||Year|Year|
||||||01/10/2021 to|01/10/2020|
||||||30/09/2022|to 30/09/2021|
||||||E|E|
|Audit Fees|||||,»6|3,396|
|Trustees'|remuneration||||||
##
||||Total for the|Total for the|
|---|---|---|---|---|
||||Year|Year|
||||01/10/2021 to|01/10/2020|
||||30/09/2022|to 30/09/2021|
||||E|E|
|Market value as at 1stOctober|||2,896,807|2,188,379|
|Additions|||300,000|100,000|
|Disposal Proceeds|||0|0|
|Net investments
gains / (losses)|||(344,701)|608,428|
|Market value as at 30th September|||2,852,106|2,896,807|
|Historical|cost as at 30th September||2,590,854|2,290,854|
|UK listed investments
are represented||by;|||
|Investment|trusts and unit trusts||2,852,106|2,896,807|
||||2,852,106|2,896,807|
##
|||||||||Totalforthe|Total for the|
|---|---|---|---|---|---|---|---|---|---|
|||||||||Year|Year|
|||||||||01/10/2021 to|01/10/2020|
|||||||||30/09/2022|to 30/09/2021|
|||||||||E|E|
|Gift aid accrued income||||||||560|19,060|
|Legacy|accrued income|||||||0|100,000|
|||||||||560|119,060|
|11
Creditors:||amounts|falling due within|one year||||||
|||||||||Totalforthe|Total for the|
|||||||||Year|Year|
|||||||||01/10/2021 to|01/10/2020|
|||||||||30/09/2022|to 30/09/2021|
|||||||||E|E|
|Accrual|s|||||||20,715|13,354|
|12a
Statement||of Funds|—current year|||||||
|||||||||Investment||
||||At|||Transfers||Gains/|At|
||||01/10/2021|Income|Expenditure|In/Out||(Losses)|30/09/2022|
||||E||E|||E|E|
|General
Fund|||1,096,930|57,084|(23,866)|||(109,541)|1,020,607|
|Designated
Funds||||||||||
|Perutz Fund|||331,290|15,819|(1,500)|||(33,499)|312,110|
|Milstein
Fund|||597,302|25,224|(43,781)|||(56,096)|522,649|
|AstraZeneca||||||||||
|Lecture Series|||3,876|21,008|(1,761)|||(2,241)|20,882|
|Michael||||||||||
|Neuberger||||||||||
|Studentship|||2,067|297|||||2,364|
|Total||||||||||
|Unrestricted|funds||2,031,465|119,432|(70,908)|||(201,377)|1,878,612|
|Restricted funds||||||||||
|Steitz (formerly||Brenner)||||||||
|Postdoc Prize|||11,138|34,341|(14,836)|||(2,970)|27,673|
|Sangamo Aaron||King||||||||
|Symposium|||10,497|173|(6,697)|||(385)|3,588|
|GSA/PALFund|||0|2,606|(178l|||(236)|2,192|
|Jeantet||||||||||
|Ramakrishnan|||363,621|16,564|(145)|||(36,836)|343,204|
|Ieantet Winter|||646,888|29,479|0|||(65,558)|610,809|
||||1,032,144|83,163|(21,856)|||(105,985)|987,466|
|Expendable||||||||||
|Endowments||||||||||
|Agouron|||254,979|11,619||||l25,840)|240,758|
|Grigg Fund|||113,464|5,171||||(11,499)|107,136|
||||368,443|16,790||||(37,339)|347,894|
|Total||||||||||
|restricted
funds|||1,400,588|99,953|l21,856)|||(143,324)|1,335,360|
|Totalfunds|||3,432,052|219,385|(92,764)||0|(344,701)|3,213,972|
##
||||||||Investment||
|---|---|---|---|---|---|---|---|---|
||||At|||Transfers|Gains/|At|
||||01/10/2020|Income|Expenditure|In/Out|(Losses)|30/09/2021|
||||E|E|E|E|E|E|
|General Fund|||682,594|237,960|(5,775)||182,151|1,096,930|
|Designated|Funds||||||||
|Perutz Fund|||258,184|13,576|(1,001)|0|60,531|331,290|
|Milstein
Fund|||499,477|22,643|(33,952)|0|109,134|597,302|
|AstraZeneca|||||||||
|Lecture Series|||3,020|148|||708|3,876|
|Michael|||||||||
|Neuberger|||||||||
|Studentship|||2,067||||0|2,067|
|Total|||||||||
|Unrestricted|funds||1,445,342|274,327|(40,729)|0|352,524|2,031,465|
|Restricted funds|||||||||
|Steitz (formerly||Brenner)|||||||
|Postdoc Prize|||5,929|15,863|(12,689)|0|2,035|11,138|
|Sangamo Aaron||Klug|||||||
|Symposium|||8,181|398||0|1,918|10,497|
|Jeantet|||||||||
|Ramakrishnan|||284,438|13,784|(1,039)|0|66,438|363,621|
|Jeantet Winter|||504,171|24,523|0|0|118,194|646,888|
||||802,719|54,568|(13,728)|0|188,585|1,032,144|
|Expendable|||||||||
|Endowments|||||||||
|Agouron|||198,725|B,eee|||46,588|254,979|
|Grigg Fund|||88,432|4,301|||20,731|113,464|
||||287,157|13,967|||67,319|368,443|
|Total|||||||||
|restricted funds|||1,089,876|68,535|(13,728)|0|255,904|1,400,588|
|Totalfunds|||2,535,218|342,862|(54,456)|0|808,428|3,432,0 2|
##
##
##
##
##
|||||||Expendable||
|---|---|---|---|---|---|---|---|
||||General|Designated|Restricted|Endowments|Total|
||||Funds|Funds|Funds|Funds|Funds|
||||E|E|E|E|E|
|Investments|||905,695|761,401|876,286|3DB,724|2,852,106|
|Current|Assets||127,229|104,824|111,358|39,170|382,581|
|Current|Liabilities||(12,317)|(8,220)|(178)|0|(20,715)|
|Net Assets||at||||||
|30September 2022|||||||3,213,972|
|13b||Analysis|of Net Assets|between
Funds - prior year||||
|||||||Expendable||
||||General|Designated|Restricted|Endowments|Total|
||||Fullds|Funds|Funds|Funds|Funds|
||||f|f|E|E|E|
|Investments|||925,858|788,789|871,176|31D,982|2,896,807|
|Current|Assets||174,476|152,895|163,768|57,461|548,600|
|Current|I iabilities||(3,404)|(7,150)|(2,800)|0|(13,354)|
|Net Assets||at||||||
|30September 2022|||1,096,930|934,535|1,032,144|||
##
##
##